Tazeen Ahmad
Stock Analyst at B of A Securities
(2.48)
# 2,266
Out of 4,778 analysts
197
Total ratings
44.3%
Success rate
-0.68%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $302 → $325 | $281.02 | +15.65% | 3 | Mar 21, 2025 | |
| STRO Sutro Biopharma | Downgrades: Underperform | $11 → $1 | $0.76 | +30.99% | 2 | Mar 14, 2025 | |
| ARVN Arvinas | Maintains: Buy | $54 → $28 | $8.13 | +244.40% | 2 | Mar 12, 2025 | |
| PTCT PTC Therapeutics | Upgrades: Neutral | $41 → $55 | $56.25 | -2.22% | 16 | Mar 11, 2025 | |
| MRUS Merus | Maintains: Buy | $73 → $70 | $46.96 | +49.06% | 5 | Mar 10, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $42 → $40 | $3.70 | +981.08% | 4 | Mar 10, 2025 | |
| DNLI Denali Therapeutics | Maintains: Buy | $30 → $28 | $14.14 | +98.02% | 2 | Mar 10, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $184 → $179 | $116.18 | +54.07% | 3 | Feb 7, 2025 | |
| PRTA Prothena Corporation | Maintains: Neutral | $26 → $22 | $12.65 | +73.91% | 5 | Dec 19, 2024 | |
| KALV KalVista Pharmaceuticals | Initiates: Buy | $22 | $12.50 | +76.00% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $1.51 | +98.68% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $61 → $47 | $23.78 | +97.65% | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $68 → $90 | $62.10 | +44.93% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $8.63 | +73.81% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $48 → $52 | $52.93 | -1.76% | 7 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $6 | $8.53 | -29.66% | 14 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $191 | $161.11 | +18.55% | 8 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $150 | $97.16 | +54.39% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $3.12 | -35.79% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $535 → $607 | $604.86 | +0.35% | 3 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $166 → $213 | $73.61 | +189.38% | 21 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $38.72 | +96.31% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $22 | $17.11 | +28.58% | 13 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $0.97 | +1,341.66% | 2 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $2.48 | +303.23% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $0.90 | +564.38% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $7.52 | +99.47% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $15.22 | -27.73% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $8.07 | +23.92% | 11 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $1.62 | +23.46% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $0.70 | +762.81% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $11.50 | +30.43% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $35.80 | +67.62% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.15 | +1,297.38% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $8.01 | +437.16% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $162.76 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $4.12 | +7,181.55% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $0.89 | +911.80% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $24.56 | +95.44% | 6 | Oct 10, 2018 |
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $302 → $325
Current: $281.02
Upside: +15.65%
Sutro Biopharma
Mar 14, 2025
Downgrades: Underperform
Price Target: $11 → $1
Current: $0.76
Upside: +30.99%
Arvinas
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $8.13
Upside: +244.40%
PTC Therapeutics
Mar 11, 2025
Upgrades: Neutral
Price Target: $41 → $55
Current: $56.25
Upside: -2.22%
Merus
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $46.96
Upside: +49.06%
4D Molecular Therapeutics
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $3.70
Upside: +981.08%
Denali Therapeutics
Mar 10, 2025
Maintains: Buy
Price Target: $30 → $28
Current: $14.14
Upside: +98.02%
Neurocrine Biosciences
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $116.18
Upside: +54.07%
Prothena Corporation
Dec 19, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $12.65
Upside: +73.91%
KalVista Pharmaceuticals
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $12.50
Upside: +76.00%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $1.51
Upside: +98.68%
Nov 6, 2024
Maintains: Buy
Price Target: $61 → $47
Current: $23.78
Upside: +97.65%
Oct 30, 2024
Upgrades: Buy
Price Target: $68 → $90
Current: $62.10
Upside: +44.93%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $8.63
Upside: +73.81%
Oct 14, 2024
Maintains: Neutral
Price Target: $48 → $52
Current: $52.93
Upside: -1.76%
Oct 9, 2024
Maintains: Underperform
Price Target: $11 → $6
Current: $8.53
Upside: -29.66%
Sep 23, 2024
Maintains: Buy
Price Target: $175 → $191
Current: $161.11
Upside: +18.55%
Sep 16, 2024
Maintains: Buy
Price Target: $125 → $150
Current: $97.16
Upside: +54.39%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $3.12
Upside: -35.79%
Jun 24, 2024
Reiterates: Buy
Price Target: $535 → $607
Current: $604.86
Upside: +0.35%
Jun 21, 2024
Maintains: Buy
Price Target: $166 → $213
Current: $73.61
Upside: +189.38%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $38.72
Upside: +96.31%
May 10, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $17.11
Upside: +28.58%
Apr 9, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $0.97
Upside: +1,341.66%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $2.48
Upside: +303.23%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $0.90
Upside: +564.38%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $7.52
Upside: +99.47%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $15.22
Upside: -27.73%
Jul 13, 2023
Upgrades: Buy
Price Target: $10
Current: $8.07
Upside: +23.92%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $1.62
Upside: +23.46%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $0.70
Upside: +762.81%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $11.50
Upside: +30.43%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $35.80
Upside: +67.62%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.15
Upside: +1,297.38%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $8.01
Upside: +437.16%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $162.76
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $4.12
Upside: +7,181.55%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $0.89
Upside: +911.80%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $24.56
Upside: +95.44%